Infinity Pharmaceuticals Provides Company Update and First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Infinity Pharma (INFI) Misses Q1 EPS by 6c
May 11, 2020 5:36 PM EDTInfinity Pharma (NASDAQ: INFI) reported Q1 EPS of ($0.19), $0.06 worse than the analyst estimate of ($0.13).
While COVID-19 has created challenges for Infinity and the broader life sciences community, it has also highlighted the dedication, commitment and innovation that is allowing the continued advancement of desperately needed treatments for patients, said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. Infinity remains committed to our clinical strategy which is designed to demonstrate the potential benefit of... More
